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Abstract 
 
Introduction: The therapeutical approach of patients under chronic antithrombotic 
therapy needing dental procedures causes great controversy. The increased hemorrhage 
risk associated with these procedures when the patient is undergoing this therapy must be 
taken into account relatively to the increased thrombotic risk caused by its interruption. 
The aim of this study was to review the current literature regarding antithrombotic therapy 
and its implications in medical dentistry. 
 
Materials and Methods: Research was performed from November 2015 until May 2016 
on the databases Cochrane Library, Medline (via PubMed) and Google Scholar, with the 
key-words: Anticoagulants Dental Surgery; Hemostasis; Cell-based Model Hemostasis; 
Antiplatelet Therapy Oral Surgery; New Oral Anticoagulants Dental Procedures; filtered 
by the following formats: Meta-analysis, Systematic Reviews and Randomized Control 
Trials, which were extended afterwards to include Reviews, Cohorts and Guidelines. 
Inclusion criteria consisted of articles published in the last 10 years, available in English 
or Portuguese, limited to human samples. Articles were also retrieved after analyzing the 
reference list of articles previously obtained. 
 
Results: The search yielded 1242 results, of which 47 were selected for inclusion, and 21 
additional articles were obtained from the reference lists of other articles. Results point 
to the fact that, currently, several authors suggest the execution of the procedures without 
therapy modification or discontinuation, emphasizing preventive local hemostatic 
measures, with the interruption of antithrombotic therapy before surgical interventions 
possibly leading to severe consequences.  
 
Conclusion: Minor oral surgery procedures are considered to be of low hemorrhagic risk. 
Therefore, there is no indication for the interruption of antithrombotic therapy, provided 
there are no additional risk factors, the patient is stably anticoagulated, and local 
hemostatic measures are properly applied. However, patients requiring extensive 
oral/maxillofacial surgery may need discontinuation of oral anticoagulants 
preoperatively, but always in conjunction with the treating physician.  
 
Key-words: Antithrombotic Therapy, Dental Procures, Hemorrhage/Thrombotic Risk. 
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Resumo 
 
Introdução 
Problemas sistémicos como embolia pulmonar, fibrilhação atrial, válvula cardíaca 
artificial, acidente vascular cerebral, entre outras patologias sistémicas, estão na base do 
tratamento profilático com terapia antitrombótica (Oake et col, 2008; António et col, 
2008; Nematullah et col, 2009; Araújo et col, 2010; Van Diermen et col, 2013).  
Desta terapêutica destacam-se os antiagregantes plaquetários e os anticoagulantes. 
Os antiagregantes plaquetários, como o AAS, atuam na hemostase primária, 
correspondente à formação de trombo plaquetário. Os anticoagulantes, como a varfarina, 
atuam na hemostase secundária, relativa à formação da rede de fibrina e coágulo (Filho 
et col, 2013; Napeñas et col, 2013).  
Os anticoagulantes orais convencionais, ou VKAs - antagonistas da vitamina K 
(essencial na produção de vários fatores de coagulação) – constituem, há mais de 60 anos, 
a terapia de primeira linha para a profilaxia de fenómenos tromboembólicos (Mookadam 
et col, 2015). São fármacos com baixo custo, eficácia comprovada e com antídoto 
específico em caso de hemorragia, que possibilita suspender a medicação em casos de 
urgência (Cid-Conde & Lopez-Castro, 2013). No entanto, apresentam limitações que 
afetam a qualidade de vida dos pacientes e aumentam a morbilidade: janela terapêutica 
estreita, resposta imprevisível, necessidade sistemática de controlo da hemorragia, 
requerem um acompanhamento de rotina, ajustes de dose frequentes e apresentam 
numerosas interações medicamentosas e alimentares (Cid-Conde & Lopez-Castro, 2013; 
Mookadam et col, 2015).  
Neste sentido, os novos anticoagulantes orais (NOACs), não dependentes da 
vitamina K, atuando diretamente sobre fatores de coagulação específicos, mostram 
promessa como uma alternativa ideal à terapia convencional (Mookadam et col, 2015). 
Na Medicina Dentária, as principais preocupações no tratamento de pacientes que tomam 
NOACs - inibidores diretos da trombina e inibidores do fator Xa - é o risco de hemorragia 
e a ausência de um antídoto específico (Isola et col, 2015; Costantinides et col, 2016). 
O crescimento do número de indivíduos submetidos a terapêutica antitrombótica 
reflete-se nos consultórios dentários (Araújo et col, 2010; Isola et col, 2015; Paraschiv et 
col, 2015). A abordagem aos doentes a realizar terapêutica crónica antitrombótica com 
necessidade de intervenções estomatológicas continua a suscitar grande controvérsia 
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(Sacco et col, 2007; António et col, 2008; Van Diermen et col, 2013; Isola et col, 2015). 
A maioria dos profissionais recomenda suspender ou diminuir a dosagem dos 
anticoagulantes, mas trabalhos recentes mostram que esta conduta causa um risco 
aumentado para o paciente (Araújo et col, 2010; Van Diermen et col, 2013). O aumento 
do risco hemorrágico, associado aos procedimentos realizados em medicina dentária em 
pacientes em que esta terapêutica é mantida, deve ser pesado relativamente ao risco 
trombótico acrescido causado pela sua interrupção (Nematullah et col, 2009; Wahl, 2014; 
Paraschiv et col, 2015). Atualmente, vários autores sugerem a execução das intervenções 
dentárias sem modificação ou interrupção da terapia, dando ênfase às medidas 
hemostáticas locais de prevenção, executadas no pré, peri e pós-operatório, para que a 
prevenção de hemorragia seja conseguida (Madrid & Sanz, 2009; Nematullah et col, 
2009; Araújo et col, 2010; Firriolo & Hupp, 2012).  
Os objetivos deste estudo passam por fazer um levantamento dos principais riscos 
associados a pacientes submetidos a esta terapia e dos protocolos de abordagem para estes 
pacientes em Medicina Dentária, relativamente à interrupção ou não do tratamento 
aquando da realização de intervenções nesta área, e outras modificações ao plano de 
tratamento, possibilitando uma prática segura para médico e paciente. 
 
Materiais e Métodos 
A pesquisa de evidência pertinente ao tema foi realizada a partir de Novembro de 
2015 até Maio de 2016, nas bases de dados Cochrane Library, Medline (via PubMed) e 
Google Scholar, com as palavras-chave: Anticoagulants Dental Surgery; Hemostasis; 
Cell-based Model Hemostasis; Antiplatelet Therapy Oral Surgery; New Oral 
Anticoagulants Dental Procedures.  
Os seguintes formatos foram considerados para inclusão: Meta-análises, Revisões 
Sistemáticas e Randomized Control Trials, que foram estendidos mais tarde para incluir 
Revisões Literárias, Coortes e Guidelines. Os critérios de inclusão consistiram de artigos 
publicados nos últimos 10 anos, disponíveis em Inglês ou Português, limitado a amostras 
humanas. Mais artigos foram obtidos após análise das referências bibliográficas dos 
artigos previamente obtidos. 
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Resultados 
A pesquisa resultou em 1242 resultados, dos quais 47 foram selecionados para 
inclusão, e 21 artigos adicionais foram obtidos a partir das referências bibliográficas de 
outros artigos.  
Os resultados apontam para o fato de que, apesar do risco hemorrágico, a 
suspensão de fármacos antiagregantes aumenta a morbilidade perioperatória, não só 
devido aos efeitos diretos da sua suspensão, mas também por causa de um possível efeito 
rebound, como é o caso da síndrome de interrupção da aspirina, promovido pelo aumento 
de tromboxano A2 e redução da fibrinólise. Consequentemente, suspender a terapia 
antiagregante antes de realizar procedimentos médico-cirúrgicos pode causar efeitos 
catastróficos (Van Diermen et col, 2009; Coelho, 2015). 
Vários estudos confirmaram a não existência de um aumento clinicamente 
significativo do risco hemorrágico pós-operatório após intervenções dentárias invasivas 
em pacientes sob mono ou dupla terapia antiagregante plaquetária (Morimoto et col, 
2008; Morimoto et col, 2009; Napeñas et col, 2009; Lillis et col, 2011; Park et col, 2012; 
Dézsi et col, 2015). 
Outros estudos mostraram que as complicações hemorrágicas associadas com a 
anticoagulação são três vezes menos prováveis de ocorrer do que complicações 
tromboembólicas graves, incluindo a morte, em pacientes cuja terapia anticoagulante foi 
interrompida (Al-Mubarak et col, 2007; Araújo et col, 2010). Para pacientes que tomam 
varfarina e que apresentam um INR estável entre 2-4, os estudos indicam que o risco de 
hemorragia significativa é muito pequeno (Bajkin et col, 2009; Madrid & Sanz, 2009; 
Nematullah et col, 2009; Okamoto et col, 2014; Bajkin et col, 2014; Isola et col, 2015). 
As indicações mais atuais sobre a interrupção de NOACs sugere que os pacientes 
que os tomam podem submeter-se a procedimentos dentários invasivos sem alteração da 
dose (O'Connell, 2014; Tsolka, 2014; Paraschiv et col, 2015; Costantinides et col, 2016). 
Quase todos os estudos propõem medidas de hemostase local para prevenção e 
controlo da hemorragia, incluindo: aplicação de pressão e sutura, anestesia com 
vasoconstritor, usando as técnicas infiltrativa e intraligamentar quando possível, esponjas 
de gelatina com solução de trombina, bochechos com soluções hemostáticas, (Sacco et 
col, 2007; Bajkin et col, 2009; Firriolo & Hupp, 2012; O'Connell, 2014; Okamoto et col, 
2014; Paraschiv et col, 2015). 
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Conclusão 
A maior parte das intervenções em Medicina Dentária são consideradas de baixo 
risco hemorrágico. Portanto, não há indicação para a interrupção de antiagregantes 
plaquetários, incluindo a terapia antiagregante dupla, antes de procedimentos dentários 
invasivos (Guyatt et col, 2012; Gerstein et col, 2012; Guyatt et col, 2012; Van Diermen 
et col, 2013; Wahl, 2014). Verificou-se também que os estudos mais recentes defendem 
a ideia de que a terapia com VKAs não deve ser interrompida (Bajkin et col, 2009; Madrid 
& Sanz, 2009; Nematullah et col, 2009; Firriolo & Hupp, 2012; Van Diermen et col, 
2013), desde que não existam fatores de risco adicionais e que o paciente esteja 
estavelmente anticoagulado (Araújo et col, 2010). 
Concluiu-se ainda que, em pacientes com função renal normal tomando NOACs, 
procedimentos dentários invasivos podem ser realizados sem interrupção da medicação 
(O'Connell, 2014; Tsolka, 2014; Paraschiv et col, 2015; Costantinides et col, 2016). 
No entanto, pacientes que necessitam de cirurgia oral extensa ou maxilofacial, 
podem precisar de interromper os anticoagulantes orais no pré-operatório, sendo que esta 
decisão não deve ser tomada sem consultar o médico assistente (Firriolo & Hupp, 2012; 
O’Connell, 2014; Tsolka, 2014; Paraschiv et col, 2015; Costantinides et col, 2016).  
Várias publicações provam a importância e a eficácia de medidas hemostáticas 
locais pré, peri e pós-operatórias, na prevenção e controlo do risco hemorrágico (Araújo 
et col, 2010; Paraschiv et col, 2015). 
 
Palavras-chave: Terapia antitrombótica, Procedimentos Dentários, Risco 
trombótico/hemorrágico. 
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1. Introduction 
 
1.1 Hemostasis 
 
Hemostasis includes a set of well-regulated processes governing blood 
coagulation, platelet activation and vascular repair. It is fundamentally responsible for the 
spontaneous arrest of bleeding after a vascular lesion, by initiating a series of vascular 
events and activating extracellular receptors which work in harmony in order to remedy 
the damage (Versteeg et al, 2013; Yau et al, 2015). Coagulation is subsequently 
attenuated by the plethora of inhibitors that prevent excessive clot formation and eventual 
thrombosis. Thus, the formation and dissolution of a blood clot consists of physiological 
processes that result in a dynamic balance between procoagulant and anticoagulant 
mechanisms (Yau et al, 2015). 
 
Traditionally, the occurrence of blood coagulation is described in two phases – 
primary hemostasis and secondary hemostasis – in which initially occurs platelet 
aggregation to form a platelet plug, and then follows the activation of the coagulation 
system, which leads to the formation fibrin clot (Cañigral et al, 2010; Yau et al, 2015). 
However, the representations of this process evolved significantly, currently 
demonstrating the complex interrelationship between platelets, coagulation system and 
vessel walls, a relationship essential in the formation of the clot. This intrinsic network 
can be described as the cellular model of coagulation. In this model, hemostasis is 
described in three stages: initiation, amplification and propagation (Yau et al, 2015). 
 
1.2 Cellular Model 
1.2.1 Initiation 
Initiation occurs after vascular injury with the activation of the endothelium and 
the exposure of sub-endothelial cells. The adhesion of platelets to these components of 
the sub-endothelium requires specific receptors, which are located in the platelet’s cell 
membrane. Major membrane receptors are designated glycoprotein (GP) receptors I, II, 
III, and IV. GPIb receptor has been identified as binding von Willebrand’s factor (VWF), 
which is essential for platelet adhesion. Another major GP receptor is the IIb-IIIa 
complex, which is considered the most important adhesive receptor for platelet 
aggregation. In its active conformation, GPIIb-IIIa binds to several bivalent ligands, 
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particularly fibrinogen, VWF and fibronectin. GPIIb-IIIa activating agents comprise 
several soluble agonists, which can activate and trap nearby platelets. These agents 
include, among others, ADP (released from platelet-dense granules), thromboxane A2 
(produced by the platelet), and thrombin (formed at the platelet’s surface) (Monroe & 
Hoffman, 2006; Versteeg et al, 2013). 
 
Platelets can also become activated from soluble agonists forming at the site of 
the thrombus. Those soluble agonists released from dense granules of activated platelets 
include small molecules such as ADP, ATP, GDP, 5-HT, pyrophosphate, magnesium and 
calcium (essential regulator of platelet activation), which precipitate a number of positive 
feedback cascades leading to rapid activation of large numbers of platelets (Golebiewska 
& Poole, 2015). In parallel to these events, activated endothelial cells express a 
procoagulant molecule, the tissue factor (TF), which binds to the FVII. TF acts as a 
cofactor for FVII in order to promote proteolysis and activation of the latter to become 
FVIIa, with TF also binding to FVIIa to form the complex TF/FVIIa. This complex will 
produce the proteolytic cleavage of FIX and FX in order to obtain FIXa and fXa. The first 
serves to generate more FXa, which in turn generates thrombin (Monroe & Hoffman, 
2006; Yau et al, 2015). 
 
1.2.2 Amplification 
 At this stage, circulating platelets adhering to the injury site become activated by 
thrombin to form a platelet aggregate. This provides a surface for the activation of other 
procoagulant factors. Proteolytic cleavage of FV and FVIII into FVa and FVIIIa by 
thrombin occurs concomitantly. In addition, thrombin will also convert FXI into FXIa, 
which will promote more generation of FIXa (Romney & Glick, 2009; Versteeg et al, 
2013; Yau et al, 2015). 
 
1.2.3 Propagation 
 In this final stage occurs the amplification of thrombin generation on the surface 
of activated platelets. FVa binds to FXa to form a prothrombinase complex, while FVIIIa 
binds to FIXa to form the tenase complex. These two complexes serve to increase the 
action of FXa and FIXa generating sufficient amounts of thrombin to produce a large 
amount of insoluble fibrin (Monroe & Hoffman, 2006; Yau et al, 2015). Still at this stage, 
11 
 
the thrombin will cleave FXIII into FXIIIa, which will connect fibrin strands through 
covalent cross-links to form a large network of fibrin. This network, along with the 
previously formed platelet aggregate, produce a stable clot that will seal the wound site 
and prevent excessive blood loss (Romney & Glick, 2009). 
 
1.3 Endogenous Regulation of the Coagulation System 
 
 Since the blood coagulation system is a potent, highly effective process, tight 
regulation of the blood coagulation system is essential to prevent unnecessary clot 
formation. Any perturbations of the regulatory pathways can accordingly culminate in 
thrombosis (Chapin & Hajjar, 2015; Yau et al, 2015).  
 
First, circulating protease inhibitors, such as antithrombin, heparin cofactor II, 
tissue factor pathway inhibitor (TFPI), and C1 inhibitor, eliminate activated coagulation 
factors by attacking their active sites. The second anticoagulant modality is provided by 
the enzyme-based protein C/protein S pathway, which is implicated in endothelial-based 
pathways of coagulation inactivation (Versteeg et al, 2013). In this pathway, fVa and 
fVIIIa are inactivated in the presence of thrombomodulin catalyst and endothelial protein 
C receptor (EPCR) (Yau et al, 2015). Collectively, these individual events come together 
to ensure that the blood coagulation system is highly regulated. Table 1 summarizes the 
respective targets for all the aforementioned inhibitors. 
 
Inhibitor Target(s) 
Antithrombin Thrombin, FIXa; FXa, FXIa, FXIIa 
TFPI FXa, TF/FVIIa 
Heparin Cofactor II Thrombin 
C1 Inhibitor FXIa, FXIIa, Kallikrein 
Protein C Pathway Thrombin 
Table 1: Targets of Coagulation Inhibitors 
 
1.4 Current Concepts of Antithrombotic Therapy 
 
Systemic problems such as pulmonary embolism, atrial fibrillation (AF), artificial 
heart valve, stroke, arterial or deep vein thrombosis, acute myocardial infarction, among 
other systemic pathologies, constitute the basis for the need of prophylactic treatment 
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with antithrombotic therapy (Oake et al, 2008; António et al, 2008; Nematullah et al, 
2009; Araújo et al, 2010; Van Diermen et al, 2013). In this therapy, the drugs that stand 
out are the antiplatelet agents and anticoagulants. Antiplatelet drugs, such as aspirin, work 
in primary hemostasis, corresponding to the formation of the platelet thrombus. 
Anticoagulants, such as heparin and warfarin, work in secondary hemostasis, relative to 
the formation of the fibrin network and blood clot (Filho et al, 2013; Napeñas et al, 2013). 
 
Conventional oral anticoagulants, or VKAs – vitamin K antagonists (vitamin K is 
essential in the production of several coagulation factors) – constitute the first line therapy 
in the prophylaxis of thromboembolic events such as AF (Mookadam et al, 2015). For 
over 60 years, VKAs, especially warfarin and acenocoumarol, have been shown, in 
several studies, to reduce the risk of stroke in 70% in patients with atrial fibrillation when 
correctly anticoagulated compared with a reduction of only 22% provided by antiplatelet 
drugs. Therefore, oral anticoagulants are recommended in AF patients at moderate-high 
risk for stroke and tromboembolism (Cid-Conde & Lopez-Castro, 2013; Johnston, 2015).  
 
VKAs are drugs with proven efficacy and a specific antidote, which can be given 
in case of bleeding. Moreover, there is the possibility of discontinuing medication 
urgently and at low cost (Cid-Conde & Lopez-Castro, 2013). However, VKAs have 
limitations that affect the quality of life of patients and increase morbidity: narrow 
therapeutic window (International Normalized Ratio, INR 2.0-3.0), unpredictable 
response, systematic control of bleeding, require routine monitoring, frequent dose 
adjustments and numerous food and drug interactions (Cid-Conde & Lopez-Castro, 2013; 
Mookadam et al, 2015). In this sense, the novel oral anticoagulants (NOACs), non-
vitamin K dependent, acting directly on specific coagulation factors, show promising 
results as an ideal alternative to conventional therapy (Mookadam et al, 2015). However, 
it is essential to understand how they differ from VKAs, how they should be monitored, 
and which precautions should be taken regarding the therapeutic adjustments when 
medical and dental procedures are performed. 
 
In dentistry and oral surgery, the major concerns in treatment of patients taking 
NOACs (direct thrombin inhibitors and factor Xa inhibitors) are the risk of hemorrhage 
and the absence of a specific reversal agent. The degree of renal function, the complexity 
of the surgical procedure and the patient’s risk of bleeding due to other concomitant 
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causes, constitute the most important factors to consider during surgical dental treatment 
of patients taking NOACs (Isola et al, 2015; Costantinides et al, 2016). 
 
It is paramount that the clinician considers that the number of patients taking 
NOACs is rapidly increasing. In addition, since available data is not sufficient to establish 
an evidence-based dental management, the dentist must use caution and attention when 
treating patients taking these drugs (Costantinides et al, 2016). 
 
There has been an increase in the number of patients undergoing antithrombotic 
therapy and in need of medical and dental care (Araújo et al, 2010; Isola et al, 2015; 
Paraschiv et al, 2015). This is easily justified by the fact that there is an increasingly aging 
population, increasing the number of anticoagulated patients, along with the current 
paradigm based on the dentition conservation as much as possible (António et al, 2008; 
Isola et al, 2015; Paraschiv et al, 2015). It is expected, therefore, a progressive increase 
of anticoagulated patients seeking dental interventions (António et al, 2008). 
 
The approach of patients under chronic antithrombotic therapy needing to undergo 
dental procedures continues to cause great controversy (Sacco et al, 2007; António et al, 
2008; Van Diermen et al, 2013; Isola et al, 2015). Most professionals recommend the 
suspension or reduction of the dosage of anticoagulants, but recent studies show that this 
behavior causes an increased risk for the patient (Araújo et al, 2010; Van Diermen et al, 
2013). Furthermore, the dentist should account for the fact that dental surgery is unlike 
other types of surgery, as major vessels are unlikely to be encountered, and the peri and 
postoperative surgical sites are easily accessible to perform local hemostatic measures, 
such as biting on gauze, absorbable gelatin sponges, and sutures (Wahl, 2014). 
 
The increased bleeding risk associated to procedures performed in dentistry when 
the patient is under oral anticoagulants or antiplatelet agents must be taken into account 
relatively to the increased risk of thrombosis caused by the interruption of antithrombotic 
therapy (Nematullah et al, 2009; Wahl, 2014; Paraschiv et al, 2015). After therapy 
interruption and its reintroduction a few days later, with initial high doses, it has been 
reported to occur a phenomenon of rebound hypercoagulation, derivative of the fact that 
the inhibition of proteins C and S occurs earlier than the inhibition of the prothrombotic 
factors, leading to a "paradoxical" thrombotic effect (António et al, 2008).  
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Several studies indicate serious embolic complications, including death, are three 
times more likely to occur in patients whose anticoagulant therapy is interrupted, than are 
bleeding complications in patients whose anticoagulant therapy is continued (and whose 
anticoagulation levels were within or below therapeutic levels) (Araújo et al, 2010). 
Currently, several authors suggest the execution of the procedures without therapy 
modification or discontinuation, with emphasis on preventive local hemostatic measures 
pre, peri and postoperatively, so that prevention of bleeding is accomplished (Madrid & 
Sanz, 2009; Nematullah et al, 2009; Araújo et al, 2010; Firriolo & Hupp, 2012). 
 
The lack of standardization of medical protocols in situations of patients taking 
antithrombotic therapy makes communication between the dentist and the attending 
physician essential, in order to avoid errors from both parts, due to lack of knowledge, or 
caused by myths on how to act in these cases (Araújo et al, 2010). 
 
The aim of this study was to review the current literature regarding antithrombotic 
therapy and its implications in medical dentistry. 
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2. Materials and Methods 
 
2.1 Research Methods 
Search for relevant literature was performed on the primary databases Cochrane 
Library (via cochranelibrary.com) and Medline (via PubMed), and the secondary 
database Google Scholar (via scholar.google.com), from November 2015 until May 26th 
2016. The following key-words were searched: Anticoagulants Dental Surgery; 
Hemostasis; Cell-based Model Hemostasis; Antiplatelet Therapy Oral Surgery; New Oral 
Anticoagulants Dental Procedures. 
 
2.2 Types of Studies Included 
The following formats were considered for inclusion in this review: Meta-
analysis, Systematic Reviews and Randomized Control Trials.  However, due to 
insufficient evidence of high scientific value, the search was extended to include Reviews, 
Cohorts and Guidelines, in order to obtain the best evidence possible. 
 
2.3 Inclusion Criteria 
Inclusion criteria consisted of articles published in the last 10 years, limited to 
those written in English or Portuguese, with the sample limited to humans. 
 
2.4 Article Selection 
 Articles were selected independently by the author, with initial screening being 
accomplished by reviewing the titles and abstracts. The full versions of the articles that 
were considered relevant or whose relevance needed to be assessed were obtained. In 
addition, the reference lists of retrieved articles on the subject were reviewed, and more 
articles were retrieved, in accordance to the inclusion criteria. 
 
2.5 Data Collection Process 
 After the initial selection and collection of the articles, they were thoroughly 
analyzed by the author in order to obtain the relevant data needed for the elaboration of 
this review. 
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3. Results 
 
According to the aforementioned criteria, the search yielded 1242 results, of 
which 47 were selected for inclusion in this paper after analyzing the titles, abstracts and 
full text. An analysis of the reference lists of the previously selected articles was also 
performed in order to obtain further data, beyond the data collected from the databases, 
which resulted in the inclusion of 21 additional articles pertinent to the subject, in 
accordance to the inclusion criteria. The 68 articles obtained are divided into: 4 
Systematic Reviews, 2 Meta-Analysis, 11 Randomized Control Trials (RCTs), 27 
Reviews, 15 Cohorts and 9 Guidelines. The following scheme shows the data collection 
process and results yielded from the search. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Medline 
via pubmed.gov 
Cochrane Library 
via cochranelibrary.com 
Google Scholar 
via scholar.google.com 
1242 Articles 
Inclusion
Criteria 
47 Articles  
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Relevance: 
Tittle 
 Abstract 
Full Text 
 
21 Articles 
From Reference Lists  
of Selected Articles 
27 
Reviews 
4 
Systematic 
Reviews 
15 
Cohorts 
2  
Meta-
Analysis 
11 
RCTs 
9 
Guidelines 
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4. Antithrombotic Therapy 
 
4.1 Antiplatelet Drugs 
 
The use of antiplatelet agents is indicated for the secondary prevention of cardiac 
and cerebrovascular diseases, more significantly for the prevention of arterial and venous 
thrombosis in patients with certain systemic conditions, such as ischemic heart disease, 
prosthetic heart valves, and those at risk for ischemic cerebrovascular accidents (Napeñas 
et al, 2013; Bajkin et al, 2014). They exert their action in the primary phase of coagulation, 
specifically in the platelet plug formation, by preventing platelets from aggregating to 
each other and adhering to blood vessel walls. This is enabled by several mechanisms 
(Pototski & Amenábar, 2007; Cardona-Tortajada et al, 2009; Guyatt et al, 2012). 
 
Cyclooxygenase inhibitors (COX-1 and COX-2) inhibit thromboxane A2-
dependent platelet activation by reversible competitive blocking of COX activity. 
Cyclooxygenase inhibitors include: acetylsalicylic acid (ASA) – COX-1 irreversible 
inhibitor; nonsteroidal anti-inflammatory drugs (NSAID) and triflusal – both COX-1 
reversible inhibitors (Pototski & Amenábar, 2007; Napeñas et al, 2013; Coelho, 2015). 
ASA creates permanent changes by blocking platelet aggregation, which last for the life 
span of the platelet (7-10 days) (Madrid & Sanz, 2009; Filho et al, 2013; Napeñas et al, 
2013; Bajkin, Urosevicb et al, 2014). Platelet aggregation and bleeding time typically do 
not return to baseline until new platelets, which were not exposed to the medication, are 
produced (Madrid & Sanz, 2009; Guyatt et al, 2012).  
 
Thienopyridines, such as clopidogrel, are irreversible blockers of P2Y12, an ADP 
receptor present in the platelets’ surface, which is necessary for the activation of the 
receptor GPIIb/IIIa complex during platelet aggregation (Napeñas et al, 2013; Coelho, 
2015). Prasugrel is a new oral antiplatelet agent (NOAP), which is also a thienopyridine 
with the same mechanism of action of clopidogrel, but with a faster onset of action, more 
potent antiplatelet effect, reduced variability and fewer drug interactions. Another NOAP, 
ticagrelor, also blocks the P2Y12 platelet receptor, but binds reversibly, which enables a 
rapid offset as well as onset of action (Dézsi et al, 2015; Johnston, 2015). Thienopyridines 
are also effective during the lifetime of the platelet (Bajkin, Urosevicb et al, 2014). 
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Dipyridamole inhibits phosphodiesterase activity, blocking cAMP decomposition 
and reducing intracellular calcium, therefore inhibiting platelet activation and 
aggregation. It is frequently used concomitantly with ASA (Pototski & Amenábar, 2007; 
Napeñas et al, 2013; Coelho, 2015; Johnston, 2015).  
 
GPIIb/IIIa receptor antagonists (tirofiban, abciximab), which are used 
intravenously, inhibit the final common pathway of platelet aggregation (Napeñas et al, 
2013; Coelho, 2015). 
 
Recently there has been a significant effort to develop tests to assess the effects of 
antiplatelet drugs on platelet function. There are several tests available to measure the 
platelet effects of aspirin, clopidogrel and other P2Y12 inhibitors. The clinical significance 
of these tests is, however, uncertain, and there is a strong correlation between their results 
and the clinical outcome. Consequently, the use of laboratory tests is not recommended 
routinely in the management of these patients (Fonseca et al, 2014). 
 
4.2 Conventional Anticoagulants 
 
Currently, the most commonly used VKAs are heparin, warfarin and 
acenocoumarol (Sacco et al, 2007; Madrid & Sanz, 2009). Heparin has a very short half-
life and thus it is usually administered intravenously for short-term use. It interferes with 
the thrombin–antithrombin pathways, by activating antithrombin and forming a complex 
which will accelerate the inhibition rate of the coagulation enzymes, specially thrombin 
and FXa, leading to a decrease in fibrin formation (Madrid & Sanz, 2009; Coelho, 2015; 
Isola et al, 2015). Although its pharmacokinetics have been improved with the 
development and introduction of low-molecular-weight heparin (LMWH), which may be 
used on an outpatient basis and have a more predictable anticoagulant response, it still 
requires narrow medical surveillance (Madrid & Sanz, 2009; Coelho, 2015). 
 
Warfarin is a coumarinic oral anticoagulant, which prevents the reduction of 
vitamin K into its active forms. It is a competitive vitamin K epoxide redutase inhibitor, 
thus inhibiting the formation of several vitamin K dependent coagulation factors (II, VII, 
IX, X), and proteins C and S. The maximum anticoagulant effect of warfarin takes 48-72 
hours to develop. It has a half-life of about 36 hours and a duration of action for a single 
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dose between 2-5 days (Al-Mubarak et al, 2007; Madrid & Sanz, 2009; O’Connell, 2014). 
Another coumarinic anticoagulant is acenocoumarol, but warfarin is the gold-standard 
(Madrid & Sanz, 2009; Paraschiv et al, 2015). They demand anticoagulation monitoring 
by measuring the INR, which was developed to incorporate the international sensitivity 
index (ISI) values and attempt to make prothrombin time (PT) results uniformly useable 
(Al-Mubarak et al, 2007; Sacco et al, 2007; Fakhri et al, 2013). INR therapeutic ranges 
depend on the disease: 2 to 3 for venous thromboembolism, stroke and atrial fibrillation; 
2.5 to 3.5 for patients with prosthetic valves (Sacco et al, 2007; Oake et al, 2008; Madrid 
& Sanz, 2009; Paraschiv et al, 2015). The incidence of bleeding is dose-dependent and 
influenced by age and the presence of comorbidities, including some medical conditions, 
polimedication, hypertension and renal or hepatic failure (Paraschiv et al, 2015). 
 
The risk of bleeding is an essential factor for the clinician’s decision of 
discontinuing the therapy or not (Jiménez et al, 2008). Thus INR monitoring is 
paramount. In spite of this, in certain non-invasive procedures, INR evaluation is not 
necessary. These procedures include: supragingival scaling, simple restorative treatment, 
local anesthetic injections (buccal infiltration, intraligamentary or mental block), 
impressions and other prosthetic procedures (Perry et al, 2007; Tsolka, 2014). Potentially 
invasive procedures, in which bleeding is predictable, will require previous evaluation of 
the aforementioned parameters, especially INR. These procedures are: local anesthesia 
by inferior alveolar or other regional nerve blocks or floor of mouth infiltrations, 
subgingival scaling and root surface instrumentation, subgingival crown and bridge 
preparations, endodontics - standard root canal treatment, simple extractions (up to 3 
teeth), incision and drainage of swellings, biopsies – which are considered moderate risk 
procedures – and extensive maxillofacial surgery, periodontal surgery, alveolar surgery 
(bone removal) and multiple extractions – which are considered high risk procedures  
(Perry et al, 2007; Douketis et al, 2008; Tsolka, 2014). 
 
4.3 Novel Oral Anticoagulants 
 
As they are relatively new and not as commonly used as warfarin is today, this 
chapter will focus on the mechanism of action and monitoring of the novel oral 
anticoagulants.  
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As it was mentioned before, VKAs present various disadvantages and limitations: 
narrow therapeutic window, unpredictable response, systematic control of bleeding, 
frequent dose adjustments and numerous food and drug interactions, which results in the 
necessity of routine monitoring. They also take several days to reach a satisfactory 
therapeutic concentration and present a complex overlap with parenteral anticoagulants 
(Cid-Conde & Lopez-Castro, 2013; Isola et al, 2015; Mookadam et al, 2015). These 
disadvantages created an impetus for the development of novel oral anticoagulants with 
a wider therapeutic index, less interactions, and a predictable level of anticoagulation at 
a specific dose. In the last few years, two new classes of oral anticoagulants – direct 
thrombin inhibitors (e.g. dabigatran etexilate), and factor Xa inhibitors (e.g. rivaroxaban, 
apixaban and edoxaban) – have been approved for use (Firriolo & Hupp, 2012; 
O’Connell, 2014; Tsolka, 2014; Costantinides et al, 2016).  
 
These NOACs are non-vitamin K dependent and, unlike warfarin, dabigatran and 
rivaroxaban are relatively small molecules that function as anticoagulants by targeting 
specific steps of the coagulation cascade (Cid-Conde & Lopez-Castro, 2013; Giugliano 
et al, 2013; O’Connell, 2014; Costantinides et al, 2016). Furthermore, they are reported 
to have fewer drug interactions, no significant food interactions, and have predictable 
pharmacokinetics, which means that they provide predictable anticoagulation at a specific 
dose, without the need for regular laboratory monitoring and adjustments of dosage 
(Granger et al, 2011; Cid-Conde & Lopez-Castro, 2013; O’Connell, 2014; Tsolka, 2014; 
Paraschiv et al, 2015; Costantinides et al, 2016). 
 
Both dabigatran and rivaroxaban are licensed for short-term primary prevention 
of venous thromboembolic events in adult patients who underwent hip or knee 
replacement surgeries, while dabigatran is also licensed for prevention of stroke and 
systemic embolism in adult patients with non-valvular atrial fibrillation (Connolly et al, 
2009; Patel et al, 2011; Cid-Conde & Lopez-Castro, 2013; O’Connell, 2014). 
 
Due to having more predictable pharmacokinetics and pharmacodynamics than 
warfarin, their use in the prevention of thromboembolic complications has shown to be 
as effective as, or in some cases even more effective than warfarin, with lower rate of 
major hemorrhage (Connolly et al, 2009; Patel et al, 2011; Paraschiv et al, 2015).  
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4.3.1 Direct Thrombin Inhibitors 
 
Dabigatran is a specific, reversible, direct thrombin inhibitor that inhibits both free 
and fibrin-bound thrombin. It prevents the conversion of fibrinogen into fibrin by binding 
itself to the active site on the thrombin molecule (factor IIa) (Firriolo & Hupp, 2012; Cid-
Conde & Lopez-Castro, 2013; O’Connell, 2014; Isola et al, 2015; Johnston, 2015). It has 
a rapid onset of action with a peak plasma concentration at 0.5-4 hours, with a half-life 
elimination is 12-14 hours in healthy patients, 14-17 hours in the elderly, and up to 27 
hours in patients with severe renal impairment (i.e., creatinine clearance <15-30ml/min) 
(Firriolo & Hupp, 2012; Cid-Conde & Lopez-Castro, 2013; O’Connell, 2014).  
 
Owing to the reversal of dabigatran’s effects, due to its short half-life, 
discontinuation of the drug may be sufficient to resolve minor hemorrhage, with the 
exception of patients with renal impairment (Firriolo & Hupp, 2012; O’Connell, 2014; 
Paraschiv et al, 2015). Supportive strategies to control more severe bleeding include oral 
charcoal application (for recent ingestion of dabigatran) (Costantinides et al, 2016), 
mechanical compression, surgical hemostasis, fluid replacement and transfusion of blood 
products (packed red cells or fresh frozen plasma). If these measures fail to control 
bleeding, then recombinant activated factor VII (rFVIIa) and/or hemodialysis can be 
considered (Firriolo & Hupp, 2012; Isola et al, 2015; Paraschiv et al, 2015). 
 
In an initial clinical study, part of an ongoing, multicenter, prospective cohort, 
published in June 2015, Pollack et al showed that idarucizumab – a monoclonal antibody 
fragment which rapidly and completely reversed the anticoagulant activity of dabigatran 
in 88 to 98 % of patients – is an effective reversal agent (Pollack et al, 2015). The U.S. 
Food and Drug Administration (FDA), in October 2015, approved idarucizumab for the 
treatment of patients taking dabigatran when reversal of its anticoagulant effects is needed 
for emergency procedures, or in life-threatening or uncontrolled bleeding (U.S. Food and 
Drug Administration, 2016). The European Medicines Agency (EMA), in December 
2015, decided that idarucizumab’s benefits are greater than its risks and recommended 
that it be approved for use in the EU (European Medicines Agency, 2016). As of today, 
its use is authorized in Portugal (Infarmed, 2016). 
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As it was mentioned above, unlike warfarin, routine monitoring of the 
anticoagulant effect of dabigatran is not required (Firriolo & Hupp, 2012; O’Connell, 
2014; Paraschiv et al, 2015). However, certain situations, such as emergency surgery, 
may require assessment of anticoagulation. This cannot be done by resorting to the INR, 
as this test is not sensitive enough (Firriolo & Hupp, 2012; Paraschiv et al, 2015).  
Dabigatran prolongs the activated partial thromboplastin time (aPTT), ecarin 
clotting time (ECT), and thrombin time (TT) at recommended therapeutic doses, but it 
has little effect on prothrombin time (PT)/INR at clinically relevant plasma 
concentrations (Castellone & Van Cott, 2010; Firriolo & Hupp, 2012; Paraschiv et al, 
2015; Isola et al, 2015). Therefore, the most sensitive tests used for quantifying the 
anticoagulant effects of dabigatran are the thrombin clotting time (TT) and ecarin clotting 
time (ECT). Castellone and Van Cott state that the TT test is too sensitive for monitoring 
the anticoagulant effects of DTIs (Direct Thrombin Inhibitors), such as dabigatran 
(Castellone & Van Cott, 2010). Despite being very good from a qualitative point of view, 
to assess adherence to treatment, it cannot quantify levels (Van Ryn et al, 2010). The 
activated partial thromboplastin time (aPTT) may also be used, but it is less sensitive than 
the TT and ECT tests, particularly at higher dabigatran doses (O’Connell, 2014; Paraschiv 
et al, 2015). 
 
4.3.2 Factor Xa Inhibitors 
 
Rivaroxaban is an orally-administered, selective, reversible, direct inhibitor of 
activated factor X (factor Xa), which interrupts both the extrinsic and intrinsic coagulation 
pathways, thereby inhibiting thrombin formation (Cid-Conde & Lopez-Castro, 2013; 
O’Connell, 2014, Johnston, 2015; Costantinides et al, 2016). It can inhibit free factor Xa, 
clot-bound factor Xa, and factor Xa bound to the prothrombinase complex (Firriolo & 
Hupp, 2012, Isola et al, 2015; Costantinides et al, 2016). It has a rapid onset of action 
with a peak plasma concentration at 2.5-4 hours, and its half-life is 5-9 hours in healthy 
adults, and 11-13 hours in the elderly (Firriolo & Hupp, 2012; Cid-Conde & Lopez-
Castro, 2013; O’Connell, 2014; Tsolka, 2014).  
 
Concerning a reversal agent, there is no specific antidote for rivaroxaban (Firriolo 
& Hupp, 2012; O’Connell, 2014; Paraschiv et al, 2015; Costantinides et al, 2016). In 
cases where severe bleeding occurs, certain strategies for the reversal of the effects of 
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rivaroxaban may be considered: fluid replacement, transfusion or blood products – 
recombinant activated factor VII or prothrombin complex concentrate (Isola et al, 2015; 
Paraschiv et al, 2015). 
More recently, a modified form of factor Xa is currently undergoing clinical trials 
to study the effectiveness of reversal of the effects of oral FXaIs, in order to be used as 
an antidote for these drugs (Costantinides et al, 2016). 
 
Similarly to dabigatran, routine monitoring of rivaroxaban is not required. 
However, in emergency situations where the measurement of the level of anticoagulation 
may be necessary, anti-factor Xa assay is reportedly the most accurate measurement of 
the anti-coagulant effect of rivaroxaban. Moreover, FXaIs (Factor Xa Inhibitors), 
including rivaroxaban, are reported to slightly prolong aPTT and PT (Castellone & Van 
Cott, 2010, Tsolka, 2014; Costantinides et al, 2016). Therefore, some authors aPTT and 
PT (with rivaroxaban specific calibration) may also be used (Samama et al, 2010; 
O’Connell, 2014; Paraschiv et al, 2015). 
 
Apixaban is the most recently introduced targeted oral anticoagulant. It is a 
reversible, highly selective and potent inhibitor of factor Xa, with the same therapeutic 
indications of dabigatran and rivaroxaban (Cid-Conde & Lopez-Castro, 2013; Johnston, 
2015; Costantinides et al, 2016). It inhibits and delays the generation of thrombin without 
significantly affecting platelet aggregation (Cid-Conde & Lopez-Castro, 2013). Its half-
life is about 12 hours and it also has a rapid onset of action, reaching peak plasma 
concentration in 1-3 hours (Tsolka, 2014; Costantinides et al, 2016). Apixaban has low 
renal elimination so it is preferred in elderly patients and those with decrease renal 
function (Paraschiv et al, 2015; Johnston, 2015). 
 
As rivaroxaban, no specific reversal agent exists for apixaban. In situations of 
normal bleeding, the delay or discontinuation of the next dose can be sufficient to resolve 
bleeding. In emergency situations, when severe bleeding occurs, recombinant factor VIIa, 
recombinant factor Xa or activated thrombin complexes can be used (Costantinides et al, 
2016). 
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5. Treatment Planning Alterations/Recommendations 
 
5.1 Antiplatelet Drugs 
 
There is some controversy over whether antiplatelet therapy should be maintained 
or suspended prior to elective dental procedures (Grines et al, 2007; Napeñas et al, 2013). 
Girotra et al, in 2013, evaluated the association between postoperatory risk of prolonged 
bleeding and various types of minor surgical interventions. They found a subtle, yet 
statistically significant, association between these variables, verifying that prolonged 
bleeding occurred independently of the type of minor procedure. (Girotra et al, 2014). 
 
In spite of the hemorrhagic risk, the suspension of antiplatelet drugs increases 
perioperatory morbidity, not only due to the direct effects of their suspension, but also 
because of a possible rebound effect, as is the case of aspirin discontinuation syndrome, 
promoted by the increase of thromboxane A2 and the reduction of fibrinolysis. 
Consequently, suspending antiplatelet therapy before performing medico-surgical 
procedures might cause catastrophic effects (Van Diermen et al, 2009; Coelho, 2015). 
Moreover, in patients with coronary artery disease, discontinuation of chronic antiplatelet 
therapy poses a significant risk for acute coronary events, which can result in death 
(Napeñas et al, 2013). 
 
The American Heart Association (AHA) and the American College of Cardiology 
(ACC) recommend not to discontinue the therapy in patients undergoing antiplatelet 
monotherapy with ASA, i.e., in patients treated with a single antiplatelet drug. In cases 
where patients are in a therapeutic regimen with dual antiplatelet therapy, i.e., treated with 
two antiplatelet agents, needing to undergo elective procedures in which there is high risk 
of bleeding, they recommend postponing the surgery, if possible, until the appropriate 
course of antiplatelet therapy is completed (Grines et al, 2007). 
 
According to the American College of Chest Physicians (ACCP), in their 2012 
guidelines, in procedures of minor hemorrhagic risk, such as most dental procedures, it is 
recommended to keep the antiplatelet therapy with ASA in cases of secondary prevention 
(Guyatt et al, 2012). 
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In Annals of Surgery, Gerstein et al, in an article published in 2012, stated that in 
patients undergoing antiplatelet treatment, during dental procedures, the risk of bleeding 
increases only by 1.5 times, which does not compromise the viability of surgery, so the 
empirical discontinuation of ASA has no indication (Gerstein et al, 2012). 
 
In their guidelines from 2014, the Portuguese Society of Anesthesiology 
recommends that patients on monotherapy with ASA or under dual antiplatelet therapy 
consisting of ASA and a P2Y12 inhibitor, undergoing procedures with low risk of 
bleeding, as is the case of most dental procedures, should not suspend the therapy; the 
importance of first assessing the thrombotic and hemorrhagic risk along with the urgency 
of the procedure is also highlighted. In patients under dual antiplatelet therapy, in cases 
of high risk of bleeding and an intermediate to high thrombotic risk, the recommendation 
is to defer elective procedures and to maintain ASA and suspend the P2Y12 inhibitor in 
emergency procures. They also suggest considering bridging therapy with GPIIb/IIIa 
inhibitors when the thrombotic risk is high (Fonseca et al, 2014). The reintroduction of 
the P2Y12 inhibitor should occur within 24 hours after surgery. When the antiplatelet 
agent is clopidogrel, which reaches a maximum effect at 5-10 days, if there is an elevated 
risk of thrombosis, a loading dose (300 to 600 mg), which is a higher dose sometimes 
recommended for drugs which take a longer time to reach their maximum effect, may be 
taken in order to obtain a faster effect (Fonseca et al, 2014; Coelho, 2015).  
 
The Italian cardiological, surgical and anaesthesiological societies, in an article 
from 2014, are in agreement with most recommendations from the Portuguese Society of 
Anesthesiology. However, they recommend keeping ASA and P2Y12 combined therapy 
in patients with intermediate to high thrombotic risk undergoing non-deferrable 
procedures which present an intermediate risk of hemorrhage (Rossini et al, 2014).  
 
Results from a clinical study by Gröbe et al suggest that, despite its more invasive 
nature, oral osteotomy can be performed safely under continued antiplatelet monotherapy 
with clopidogrel or dual therapy with clopidogrel and ASA (Gröbe et al, 2015). Hanken 
et al reached the same conclusion regarding continued ASA therapy (Hanken et al, 2015). 
 
Morimoto et al, in two different studies, concluded that postoperative hemorrhage 
after periodontal surgery and teeth extractions for patients on single or dual antiplatelet 
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therapy was significantly lower than for those on combined antiplatelet/warfarin therapy 
and warfarin therapy alone (Morimoto et al, 2008; Morimoto et al, 2009). As several 
studies suggest keeping warfarin therapy for patients undergoing most dental procedures 
(which will be discussed in the next section), when the INR is below 4, it is possible to 
infer that antiplatelet therapy should not be suspended (Napeñas et al, 2013). In reality, 
the hemorrhagic risk may be a rare occurrence after dental procedures, with a low to 
negligible frequency for patients undergoing mono or dual antiplatelet therapy, as it has 
been reported in only a few cases after periodontal surgery or extensive oral surgery, 
when an excessive dosage of ASA was taken (Napeñas et al, 2009). 
 
It is also important to consider that a growing number of patients are taking 
combined oral anticoagulant and antiplatelet therapy, which is strongly recommended to 
be used only in patients with prosthetic heart valves. A prospective study by Bajkin et al, 
in 2012, concluded that teeth extractions can be performed safely while patients continue 
to receive combined anticoagulant-aspirin therapy, as long as their INR values are within 
therapeutic range and local hemostasis measures are provided (Bajkin et al, 2012). 
 
Various studies found no clinically significant increased risk of postoperative 
bleeding complications from invasive dental procedures in patients on either single or 
dual antiplatelet therapy, which supports the recommendation that there is no indication 
to alter or suspend this therapy (Morimoto et al, 2008; Morimoto et al, 2009; Napeñas et 
al, 2009; Lillis et al, 2011; Park et al, 2012; Dézsi et al, 2015). 
 
To sum up, the risks of altering or discontinuing the use of antiplatelet drugs far 
outweigh the risk of postoperative oral bleeding (Napeñas et al, 2009; Wahl, 2014). In 
the rare event of postoperative bleeding, local hemostatic measures are effective in 
addressing this complication (Morimoto et al, 2009; Napeñas et al, 2013).  
 
Regarding new oral antiplatelet agents, such as prasugrel and ticagrelor, further 
evidence is required to establish whether a period of discontinuation is necessary for 
minor oral surgery procedures (Johnston, 2015). However, Dézsi et al, in a study 
published in 2015, refer that dental extractions can be performed safely with due 
precaution in patients under dual antiplatelet therapy combining either clopidogrel and 
ASA or prasugrel and ASA (Dézsi et al, 2015). 
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5.2 Conventional Anticoagulants 
 
The management of dental procedures in patients undergoing oral anticoagulation 
must be individualized depending on the type of procedure, bleeding risk and thrombotic 
risk (Paraschiv et al, 2015). Current available information suggests that the risk of 
hemorrhage in patients undergoing invasive dental procedures (e.g. up to three dental 
extractions, up to three dental implants and periodontal surgery) is low (Van Diermen et 
al, 2013; Tsolka, 2014). 
 
Several strategies have been used for the management of anticoagulated patients 
during dental procedures. One approach is to withhold VKAs for 3–5 days prior to the 
intervention, without substitution with additional anticoagulation (Patatanian & Fugate, 
2006; Pototski & Amenábar, 2007; Sacco et al, 2007; Madrid & Sanz, 2009). However, 
this approach exposes the patient to increased thromboembolic risk for over a week while 
the INR is subtherapeutic (Patatanian & Fugate, 2006), as it would take about 4 days for 
the INR to reach the value of 1,5, and about 3 days to reach therapeutic values after being 
resumed (Pototski & Amenábar, 2007; Nematullah et al, 2009). In addition, the risk of 
thromboembolism may be increased by other factors, such as rebound hypercoagulable 
state due to discontinuation of oral anticoagulation and the hemostatic changes of the 
surgical intervention itself (Patatanian & Fugate, 2006; António et al, 2008; Madrid & 
Sanz, 2009). Therefore, the drug becomes unpredictable and a higher probability of 
occurrence of a thromboembolic event is reported (Nematullah et al, 2009; Madrid & 
Sanz, 2009; Isola et al, 2015). The scientific evidence does not support this protocol as it 
may increase the thromboembolic risk, without significantly reducing bleeding after the 
procedures (Madrid & Sanz, 2009; Van Diermen et al, 2013; O’Connell, 2014). 
 
Another approach is to withhold VKAs for 3–5 days before the procedure, while 
bridging with a parenteral anticoagulant such as LMWH, which has the advantage of 
minimizing thromboembolic risk (Patatanian & Fugate, 2006; Sacco et al, 2007; Bajkin 
et al, 2009; Nematullah et al, 2009). Nevertheless, it has disadvantages such as increased 
risk of bleeding from dual anticoagulation therapy perioperatively, expense of an 
additional anticoagulant, inconvenience of injections, and higher complexity of the 
therapeutic regimen (Patatanian & Fugate, 2006). Various studies concluded that there is 
no need for bridging therapy with LMWH in patients undergoing minor dentoalveolar 
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procedures, although this approach can be used in patients going through major oral 
surgical interventions (Pettinger & Owens, 2007; Bajkin et al, 2009). Consequently, this 
method is advocated only for patients at intermediate to high thromboembolic risk who 
are undergoing invasive procedures or surgery necessitating therapy interruption 
(Patatanian & Fugate, 2006; Pettinger & Owens, 2007). This protocol requires very subtle 
monitoring of the therapy. Moreover, the risk of thromboembolic events may be even 
higher than when warfarin is discontinued without bridging therapy, due to the fact that 
heparin may induce thrombocytopenia, which may further impair the patient’s hemostasis 
(Madrid & Sanz, 2009). 
 
A third approach is to continue oral anticoagulation perioperatively, in order to 
avoid compromising the thromboembolic protection. Several studies and guidelines 
support this practice (Patatanian & Fugate, 2006; Al-Mubarak et al, 2007; Perry et al, 
2007; Douketis et al, 2009; Bajkin et al, 2009; Madrid & Sanz, 2009; Nematullah et al, 
2009; Firriolo & Hupp, 2012). The literature does not describe any cases of severe 
postoperatory bleeding in patients who continued the therapy, whereas several cases of 
fatal thromboembolic complications were reported after cessation of oral anticoagulants 
before procedures such as dental extractions (Sacco et al, 2007; Bajkin et al, 2009). 
Recent studies have suggested that VKAs should not be discontinued in the majority of 
patients requiring outpatient dental procedures (including dental extractions and implant 
placement – as long as it does not involve autogenous bone grafts, extensive flaps or 
osteotomy preparations extending outside the bony envelope), provided local hemostasis 
is adequately maintained (Al-Mubarak et al, 2007; Perry et al, 2007; Douketis et al, 2009; 
Madrid & Sanz, 2009; Van Diermen et al, 2013; Bajkin et al, 2014).  
 
Due to the fact that dental implants have become the standard of care regarding 
the substitution of missing teeth, it is inevitable to treat an anticoagulated patient needing 
implant placement, which could be considered as comparable with or even less traumatic 
than the extraction of three teeth. Consequently, evidence does not support that dental 
implant placement is contraindicated in these patients (Madrid & Sanz, 2009). 
 
The difficulty in predicting the drop in the INR value when warfarin therapy is 
suspended and the associated risk of thromboembolism outweighs the risk of 
postoperative bleeding in patients who maintain the therapy (Al-Mubarak et al, 2007; 
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Madrid & Sanz, 2009; Okamoto et al, 2014). Moreover, other studies have shown that 
bleeding complications associated with anticoagulation are three times less likely to occur 
than serious embolic complications (including death) in patients whose anticoagulant 
therapy was interrupted (Al-Mubarak et al, 2007; Araújo et al, 2010). Notwithstanding, 
there is a concern for higher hemorrhagic risk when continuing the therapy. However, 
this can be managed by performing local hemostatic measures, such as applying local 
pressure, hemostatic mouthwashes and suturing (Patatanian & Fugate, 2006; Sacco et al, 
2007; Madrid & Sanz, 2009; Fakhri et al, 2013), which will be addressed ahead. 
 
For patients under warfarin therapy who present a stable INR between 2-4, studies 
indicate that the risk of significant bleeding is very small, hence the medico-surgical 
intervention can be performed without suspending the therapy (Perry et al, 2007; Al-
Mubarak et al, 2007; Bajkin et al, 2009; Madrid & Sanz, 2009; Nematullah et al, 2009; 
Okamoto et al, 2014; Bajkin et al, 2014; Isola et al, 2015). Furthermore, according to 
Oake et al, in a review from 2008, the risks of hemorrhage and thromboembolism are 
both minimized at INR ratios of 2–3, while ratios that are moderately higher than this 
therapeutic range appear to be safer than subtherapeutic ratios (Oake et al, 2008). 
Nonetheless, when INR values approach 4, an appreciation of the difficulty of surgery 
and the experience and surgical skills of the dentist is recommended when assessing the 
risk of bleeding. For patients who are stably anticoagulated, the determination of INR is 
recommended 72 hours prior to dental surgery (Perry et al, 2007; Johnston, 2015). When 
this is not the case, INR should be checked 24 hours before the procedure (Douketis et al, 
2012). 
 
Concerning drug interactions, patients undergoing dental surgery may be 
prescribed antibiotics to prevent endocarditis. According to Perry et al, in their 2007 
guidelines, a single dose of an antibiotic is unlikely to have any significant effect upon 
the INR. Individuals who are prescribed more than a single dose of antibiotics should 
have the INR measured 2-3 days after starting treatment (Perry et al, 2007). Macrolide 
antibiotics, including erythromycin, clarithromycin, and possibly azithromycin, are 
reported to cause significant episodes of bleeding in patients taking warfarin (Firriolo & 
Hupp, 2012). In terms of analgesic therapy, non-steroidal anti-inflammatory drugs 
(NSAIDs) and COX-2 selective inhibitors are avoided in patients receiving oral 
anticoagulants because of their antiplatelet action and the risk of over-anticoagulation and 
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hemorrhage (Perry et al, 2007; Van Diermen et al, 2013; Isola et al, 2015).  Metronidazole 
and other azole antifungals, including ketoconazole, fluconazole and itraconazole are 
reported to significantly interact with warfarin via CYP inhibition, thus augmenting its 
effects (Firriolo & Hupp, 2012; Van Diermen et al, 2013). 
 
Furthermore, in patients taking oral anticoagulants, block anesthetic techniques 
are not recommended. However, inferior alveolar nerve block is accepted in patients 
taking warfarin with INR<3. Owing to local anesthesia, intraligamentary and intraseptal 
techniques produce less bleeding complications (Paraschiv et al, 2015). 
 
Finally, patients on oral anticoagulants with co-existing systemic conditions, 
including liver disease, renal disease and thrombocytopenia, or who are taking antiplatelet 
drugs, present an increased risk of bleeding. Therefore, these patients should not go 
through surgical dental procedures in the primary care setting. In these cases, or in cases 
where patients do not present stable INR values, the treating physician should always be 
consulted on whether to suspend the therapy or not (Perry et al, 2007).  
 
5.3 Novel Oral Anticoagulants 
 
Similarly to VKAs, NOACs also increase the risk of bleeding complications 
during and after surgical procedures (Heidbuchel et al., 2013). However, Firriolo and 
Hupp, in 2012, concluded that there should not be a significant risk for serious bleeding 
after dental treatment, including most uncomplicated dental extractions, in patients with 
normal renal function and without other risk factors for bleeding (Firriolo & Hupp, 2012). 
This risk assessment is based on the type, complexity and invasiveness of the surgical 
procedure, the presence and degree of any renal impairment, and the presence of other 
risk factors for impaired hemostasis (Firriolo & Hupp, 2012; Heidbuchel et al., 2013). 
Due to lack of data in the literature, there are currently no definitive dental management 
recommendations for patients on NOACs (Paraschiv et al, 2015; Isola et al, 2015). 
 
Heidbuchel et al, in their guidelines from the EHRA (European Heart Rhythm 
Association), suggest that even in low or medium risk procedures it may be more 
advisable to schedule the intervention 18–24 hours after the last intake, and then restart 6 
hours later, skipping one dose for oral anticoagulants which are usually administered 
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twice a day (Heidbuchel et al, 2013). For procedures with a minor bleeding risk, they 
recommend the discontinuation of NOACs (DTIs and FXaIs alike) 24 hours before 
elective procedures in patients with a normal kidney function, and to take the last NOAC 
48 hours before procedures that carry a risk for major bleeding (Heidbuchel et al, 2013).  
 
5.3.1 Direct Thrombin Inhibitors 
 
Various studies demonstrated that the risk of hemorrhage for patients taking DTIs 
is similar to those taking warfarin when the INR value ranges between 2 and 3 (Connolly 
et al, 2009; Healey et al., 2012). For patients requiring simple dental extraction or minor 
oral surgery procedures (surgical dental extraction, localized periodontal surgery, 
apicectomies, incisional biopsies or excision of localized mucosal lesion), it can be 
assumed that the risk is similar to that of patients taking VKAs with the aforementioned 
INR values (Isola et al, 2015; Costantinides et al, 2016). 
 
The most current information concerning the interruption of dabigatran suggests 
that patients taking it can undergo invasive dental procedures without alteration of dose 
(O’Connell, 2014; Tsolka, 2014; Paraschiv et al, 2015). In order to reduce the risk of 
bleeding, the surgical procedures should be performed as late as possible after the most 
recent intake (Costantinides et al, 2016). Nonetheless, certain situations, as is the case of 
oral/maxillofacial surgical procedures, may require the temporary discontinuation of 
dabigatran due to concerns for possible complications resulting from excessive bleeding 
and/or impaired hemostasis. In those cases, dabigatran should be discontinued 12-24 
hours before surgery, or longer, depending on the risk of bleeding (Firriolo & Hupp, 2012; 
Tsolka, 2014; Paraschiv et al, 2015).  
 
Heidbuchel et al, in the previously mentioned guidelines, consider that in patients 
with chronic kidney disease (CKD), with a creatinine clearance (CrCl) between 50-80 
ml/min, the discontinuation of dabigatran should occur 36 hours prior to procedures with 
minor risk of bleeding and 72 hours prior to high risk interventions (Heidbuchel et al, 
2013). Additionally, consideration should be given to performing a TT or aPTT 6 to 12 
hours prior to surgery, which, if normal, indicates that the coagulation is normal and that 
the anticoagulant effect of dabigatran has resolved (Firriolo & Hupp, 2012). 
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Owing to the risk of thromboembolism, dabigatran should never be discontinued 
without prior consultation with the treating physician (O’Connell, 2014; Tsolka, 2014; 
Paraschiv et al, 2015). Dabigatran should only be recommenced postoperatively once a 
stable clot has formed, usually within 24–48 hours following surgery (Costantinides et al, 
2016), as its onset of effect is predictable and rapid, thereby minimizing the risk of 
bleeding (Firriolo & Hupp, 2012; O’Connell, 2014). 
 
Concerning drug interactions, drugs such as ketoconazole, verapamil, and 
amiodarone may increase the anticoagulant effect of dabigatran, whilst rifampicin, 
dexamethasone and carbamazepine may decrease its effect. Polimedication with 
antiplatelet agents, salicylates and other anticoagulants may increase the risk of bleeding. 
Non-cox-selective nonsteroidal anti-inflammatory drugs (NSAID) inhibit platelet 
aggregation and are associated with gastro-intestinal bleeding; therefore, it may be 
prudent to avoid their use in patients taking dabigatran. Paracetamol and opioid analgesics 
are suitable alternatives in cases such as dental extractions post-ops (Firriolo & Hupp, 
2012; O’Connell, 2014; Paraschiv et al, 2015; Isola et al, 2015; Costantinides et al, 2016). 
 
5.3.2 Factor Xa Inhibitors 
 
In general, the considerations presented above in relation to dabigatran are also 
applicable to rivaroxaban (O’Connell, 2014; Costantinides et al, 2016). Therefore, there 
is no indication to discontinue rivaroxaban for uncomplicated extractions and other 
similar invasive dental procedures in patients with normal renal function (O’Connell, 
2014; Tsolka, 2014; Costantinides et al, 2016).  
 
Similarly to dabigatran, rivaroxaban should be discontinued at least 24 hours 
before oral and maxillofacial surgery in patients with impaired hemostasis or with high 
risk of bleeding. Patients with severe renal impairment may need to discontinue its intake 
for more than 24 hours, as they show a significant increase in maximum plasma 
concentration and longer half- life of rivaroxaban (Firriolo & Hupp, 2012; Costantinides 
et al, 2016). In patients with chronic kidney disease (CKD), Heidbuchel et al suggest that 
it is advisable to suspend FXaIs 24 hours before low-risk and 48 hours before high-risk 
procedures (Heidbuchel et al, 2013). After being discontinued, rivaroxaban should only 
be restarted within 24–48 hours after the procedure, due to its rapid onset (Firriolo & 
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Hupp, 2012; Costantinides et al, 2016). As mentioned previously, local hemostatic 
measures should be employed when necessary (O’Connell, 2014). 
 
Concomitant use of rivaroxaban with CYP3A4 inhibitors (erythromycin, 
ketoconazole, and amiodarone), which can increase the risk of bleeding, or CYP3A4 
inducers (phenytoin, rifampicin), which may increase the metabolism of rivaroxaban, 
thereby decreasing the level of anticoagulation, should be avoided. Non-steroidal and 
opioid analgesics should be used with caution (Firriolo & Hupp, 2012; O’Connell, 2014; 
Costantinides et al, 2016). 
 
Regarding apixaban, as it is one of the most recently marketed FXaIs, few data or 
guidelines are available for management of dental patients taking this drug. In general, 
the same indications used for dabigratran and rivaroxaban can be valid (Costantinides et 
al, 2016). Current information shows that there is no indication to suspend apixaban 
before dental procedures in patients with no risk factors or comorbidities for increased 
bleeding. However, further studies are needed in this regard (Costantinides et al, 2016). 
Similarly to rivaroxaban, administration of potent CYP3A4 and P-glycoprotein inhibitors 
is contraindicated (Costantinides et al, 2016). Drugs such as itraconazole, ketoconazole, 
posaconazole, ritonavir and voriconazole increase the plasma concentration of apixaban. 
Carbamazepine, phenobarbital, phenytoin and rifampicin decrease its plasma 
concentrations, reducing its effect. Therefore, they should not be administered when 
taking apixaban (Paraschiv et al, 2015). 
 
5.4 Local Hemostatic Measures 
 
The dental procedures in patients under oral anticoagulants should be done with 
minimal trauma, and local measures are essential to control postoperative hemorrhage 
(Okamoto et al, 2014; Paraschiv et al, 2015).  These measures include: additional suturing 
(preferably resorbable) (Rodríguez-Cabrera et al, 2011; Tsolka, 2014), anesthesia with 
vasoconstrictor, using infiltration and intraligamentary techniques when possible 
(Pototski & Amenábar, 2007) topical thrombin powder, gelatin sponges with thrombin 
solution (that must not be used with oxidized cellulose or microfibrillar collagen because 
they inactivate thrombin), oxidized cellulose or microfibrillar collagen hemostat, 
absorbable gelatin compressed pellets, applying local pressure and electrocauterization 
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(Sacco et al, 2007; Bajkin et al, 2009; Firriolo & Hupp, 2012; O’Connell, 2014; Okamoto 
et al, 2014; Paraschiv et al, 2015). 
Other possible measures include the use of hemostatic agents, which inhibit the 
activation of plasminogen to plasmin, producing antifibrinolytic activity. The oral mucosa 
is rich in plasminogen activators, making hemostatic agents effective in the control of 
oral bleeding (Patatanian & Fugate, 2006; Madrid & Sanz, 2009). This effectiveness is 
due to the fact that the majority of postoperative bleeding episodes in anticoagulated 
patients tend to occur 2-3 days after the surgery, triggered by these plasminogen 
activators, with subsequent fibrinolysis breaking the clot (Madrid & Sanz, 2009). 
Amongst all the hemostatic agents available, only tranexamic acid (TXA) and epsilon 
aminocaproic acid (EACA) have been evaluated and used as mouthwashes. Results show 
that TXA is 6–10 times more potent than EACA (Patatanian & Fugate, 2006). Therefore, 
it is advisable to use tranexamic acid mouth rinse twice daily for 2–5 days (Costantinides 
et al, 2016) or for 1–2 days after the surgery, using 10 ml, four times a day for two minutes 
(Perry et al, 2007; Tsolka, 2014; Paraschiv et al, 2015). It is also available in the form of 
tablets or intra-venous injections, and it can be applied in a gauze soaked in 5% 
tranexamic acid (O’Connell, 2014; Bajkin et al, 2014). 
 
Okamoto et al, in a study from 2014, concluded that blue-violet LED irradiation 
combined with hemostatic gelatin sponge treatment yielded hemostasis of the extraction 
socket within 30 seconds without suture in most cases, making it another available and 
effective option for control of postoperative bleeding (Okamoto et al, 2014). 
 
Fibrin sealants also present themselves as a good and effective hemostatic 
measure (Al-Mubarak et al, 2007; Bajkin et al, 2009; Paraschiv et al, 2015). They are 
mainly derived from blood plasma and contain two components that interact during 
application, mimicking the final steps of the blood coagulation cascade and forming a 
stable fibrin clot (Paraschiv et al, 2015). They can be applied to very small blood vessels 
and to areas that are difficult to reach with conventional sutures. Therefore, they are able 
to control the bleeding by speeding up the formation of a stable clot. In addition, they 
reduce the risk of postoperative inflammation or infection as the body absorbs them 
during the healing process (Paraschiv et al, 2015). Overall, the fibrin sealants are 
particularly useful for minimally invasive procedures and for treating patients taking 
anticoagulants (Al-Mubarak et al, 2007; Bajkin et al, 2009; Paraschiv et al, 2015).  
35 
 
6. Conclusion 
 
It is possible to affirm that in minor oral surgery, the mortality and morbidity is 
superior in thromboembolic episodes in comparison with hemorrhagic episodes (António 
et al, 2008; Bajkin et al, 2009; Paraschiv et al, 2015). 
 
There is no indication to alter or discontinue antiplatelet therapy; not even dual 
antiplatelet therapy, before invasive dental procedures (Grines et al, 2007; Guyatt et al, 
2012; Gerstein et al, 2012; Van Diermen et al, 2013; Wahl, 2014; Coelho, 2015). 
 
In this literary review, it was found that the most recent studies defend the idea 
that the therapy with VKAs shouldn’t be interrupted (Bajkin et al, 2009; Madrid & Sanz, 
2009; Nematullah et al, 2009; Firriolo & Hupp, 2012; Van Diermen et al, 2013), as long 
as the patient’s INR is between the proper values that enable the performance of the 
medico-surgical procedure without added risk of bleeding (Araújo et al, 2010). 
 
Many investigations are showing clear benefits to targeted oral anticoagulants 
(NOACs) over warfarin (Firriolo & Hupp, 2012). Based on current information, in 
patients with normal renal function taking NOACs, invasive dental procedures can be 
carried out without interruption of the medication (Firriolo & Hupp, 2012; O’Connell, 
2014; Tsolka, 2014; Paraschiv et al, 2015; Costantinides et al, 2016). However, patients 
requiring oral/maxillofacial surgery may need discontinuation of oral anticoagulants 12-
24 hours preoperatively, but always in consultation with the treating physician (Firriolo 
& Hupp, 2012; O’Connell, 2014; Tsolka, 2014; Paraschiv et al, 2015; Costantinides et al, 
2016).  
 
Several publications prove the importance and efficacy of pre, peri and 
postoperatory measures in the prevention and control of the risk of bleeding, as the 
interruption of the medication creates an added risk to the patient, due to the possibility 
of thrombus formation (Araújo et al, 2010; Paraschiv et al, 2015). Other useful advice to 
dental patients on antithrombotic therapy may be to schedule the dental procedures early 
in the day and/or in the week, in order to allow more time to manage bleeding if it occurs 
(Paraschiv et al, 2015; Costantinides et al, 2016).  
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